Total | Group I | Group II | ||
---|---|---|---|---|
n = 38 | n = 27 | n = 11 | ||
Male gender, n (%) | 27 (71) | 19 (70) | 8 (73) | |
Age, years | 69.4 ± 10.7 | 70.9 ± 11.2 | 65.5 ± 7.9 | |
Past history, n (%) | ||||
Hypertension | 25 (66) | 19 (70) | 6 (55) | |
Diabetes mellitus | 16 (42) | 9 (33) | 7 (64) | |
Hyperlipidemia | 7 (18) | 4 (15) | 3 (27) | |
Smoking | 8 (21) | 4 (15) | 3 (27) | |
Atrial fibrillation | 11 (29) | 11 (41) | 0 (0) | |
Ischemic stroke | 11 (29) | 9 (33) | 2 (18) | |
Intracerebral hemorrhage | 2 (5) | 1 (4) | 1 (9) | |
Subarachnoid hemorrhage | 0 (0) | 0 (0) | 0 (0) | |
Infarct side, n (%) | ||||
Right | 20 (53) | 13 (48) | 7 (64) | |
Left | 18 (47) | 14 (52) | 4 (36) | |
Baseline NIHSS score, mean | 8.2 ± 7.5 | 10 ± 8.2 | 3.9 ± 2.4 | |
Interval from onset to treatment with edaravone and hydrogen, h | 16 ± 18.1 | 14.9 ± 18.7 | 18.8 ± 6.3 | |
Duration of treatment with edaravone and hydrogen, d | 10.8 ± 3.4 | 10.7 ± 3.5 | 11.1 ± 3 | |
Laboratory data | ||||
HbA1C,% | 6.3 ± 1.7 | 6 ± 1.4 | 7 ± 2 | |
BG, mg/dl | 145.2 ± 58.2 | 134 ± 48.9 | 171.6 ± 68.8 | |
TG, mg/dl | 116.7 ± 61.3 | 121 ± 67.7 | 107.8 ± 43.7 | |
TC, mg/dl | 194.3 ± 43.4 | 186.6 ± 38.3 | 217.3 ± 49.4 | |
LDL, mg/dl | 114.3 ± 33.7 | 109 ± 25.7 | 126.5 ± 44.7 | |
UA, mg/dl | 5.3 ± 1.4 | 5.2 ± 1.4 | 5.6 ± 0.9 | |
PT-INR | 1.14 ± 0.3 | 1.2 ± 0.3 | 1.1 ± 0.06 | |
APTT, seconds | 30.7 ± 3.9 | 31 ± 4.1 | 30.1 ± 3.2 | |
Fibrinogen, mg/dl | 336.7 ± 101.9 | 333.6 ± 107.4 | 349 ± 74.9 | |
Hct (%) | 41.3 ± 6.4 | 40.7 ± 6.7 | 42.8 ± 5.3 |